Gilead Sciences (GILD) Research & Development (2009 - 2026)
Gilead Sciences' (GILD) quarterly Research & Development came in at $1.4 billion in Q1 2026, down 0.51% YoY from $1.4 billion in Q1 2025, and down 13.38% on a QoQ basis from $1.6 billion in Q4 2025.
Gilead Sciences (GILD) Research & Development (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Research & Development data on file, last reported at $1.4 billion in Q1 2026.
- Quarterly Research & Development fell 0.51% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 billion (changed 0.47% YoY) and the FY2025 annual result came in at $5.8 billion, down 1.83% from the prior year.
- Research & Development eased to $1.4 billion in Q1 2026, from $1.6 billion in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.6 billion in Q4 2024 to a low of $1.1 billion in Q2 2022.
- A 5-year average of $1.4 billion and a median of $1.4 billion in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development rose 27.68% — and 2025, when it decreased 9.28%.
- Tracing GILD's Research & Development over 5 years: stood at $1.5 billion in 2022, then slipped by 9.04% to $1.4 billion in 2023, then climbed by 16.55% to $1.6 billion in 2024, then slipped by 3.47% to $1.6 billion in 2025, then retreated by 13.38% to $1.4 billion in 2026.
- The last three Research & Development figures came in at $1.4 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Bn |
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.58 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 1.49 Bn |
| Mar 31, 2025 | 1.38 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Jun 30, 2024 | 1.35 Bn |
| Mar 31, 2024 | 1.52 Bn |
| Dec 31, 2023 | 1.41 Bn |
| Sep 30, 2023 | 1.46 Bn |
| Jun 30, 2023 | 1.41 Bn |
| Mar 31, 2023 | 1.45 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Sep 30, 2022 | 1.15 Bn |
| Jun 30, 2022 | 1.10 Bn |
| Mar 31, 2022 | 1.18 Bn |
| Dec 31, 2021 | 1.36 Bn |
| Sep 30, 2021 | 1.10 Bn |